CY1114908T1 - Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες - Google Patents
Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντεςInfo
- Publication number
- CY1114908T1 CY1114908T1 CY20131101116T CY131101116T CY1114908T1 CY 1114908 T1 CY1114908 T1 CY 1114908T1 CY 20131101116 T CY20131101116 T CY 20131101116T CY 131101116 T CY131101116 T CY 131101116T CY 1114908 T1 CY1114908 T1 CY 1114908T1
- Authority
- CY
- Cyprus
- Prior art keywords
- alkyl
- hydrogen
- het
- alkylthio
- radical
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
- C07D215/227—Oxygen atoms attached in position 2 or 4 only one oxygen atom which is attached in position 2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/22—Oxygen atoms attached in position 2 or 4
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Quinoline Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Χρήση μιας ένωσης για την παρασκευή ενός φαρμάκου για τη θεραπευτική αγωγή μιας βακτηριακής μόλυνσης δεδομένου ότι η βακτηριακή μόλυνση είναι διαφορετική από μια Μυκοβακτηριακή μόλυνση, με την εν λόγω ένωση να είναι μια ένωση του Τύπου (Ιa) ή (Ιb), ένα φαρμακευτικώς αποδεκτό άλας προσθήκης οξέων ή βάσεων αυτής, μια τεταρτοταγής αμίνη αυτής, μια στερεοχημικώς ισομερής μορφή αυτής, μια ταυτομερική μορφή αυτής ή μια μορφή N-οξειδίου αυτής, όπου το R1 είναι υδρογόνο, αλο, αλοαλκυλ, κυανο, υδροξυ, Ar, Het, αλκυλ, αλκυλοξυ, αλκυλθειο, αλκυλοξυαλκυλ, αλκυλθειοαλκυλ, Αr-αλκυλ ή δι(Αr)αλκυλ· το p είναι 1, 2 ή 3· το R2 είναι υδρογόνο· αλκυλ· υδροξυ· μερκαπτο· προαιρετικά υποκατεστημένο αλκυλοξυ· αλκυλοξυαλκυλοξυ· αλκυλθειο· μονο ή δι(αλκυλ)αμινο όπου το αλκυλ μπορεί προαιρετικά να είναι υποκατεστημένο Αr· Ηet ή μία ρίζα του Τύπου (II)· το R3 είναι αλκυλ, Αr, Αr-αλκυλ, Ηet ή Ηet-αλκυλ· το q είναι μηδέν, 1, 2, 3 ή 4· το Χ είναι ένας ευθύς δεσμός ή CΗ2· τα R4 και R5 το καθένα ανεξάρτητα είναι υδρογόνο, αλκυλ ή βενζυλ· ή τα R4 και R5 μπορεί να ληφθούν μαζί, συμπεριλαμβάνοντας το Ν στο οποίο είναι προσαρτημένα· το R6 είναι υδρογόνο ή μία ρίζα του Τύπου (III)· το R7 είναι υδρογόνο, αλκυλ, Αr ή Ηet· το R8 είναι υδρογόνο ή αλκυλ· το R9 είναι οξο· ή τα R8 και R9 μαζί σχηματίζουν τη ρίζα - CH=CH-N=.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05107159 | 2005-08-03 | ||
EP06778081.7A EP1912647B1 (en) | 2005-08-03 | 2006-07-31 | Quinoline derivatives as antibacterical agents |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1114908T1 true CY1114908T1 (el) | 2016-12-14 |
Family
ID=35768940
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20131101116T CY1114908T1 (el) | 2005-08-03 | 2013-12-11 | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες |
Country Status (29)
Country | Link |
---|---|
US (1) | US8017606B2 (el) |
EP (1) | EP1912647B1 (el) |
JP (1) | JP5410753B2 (el) |
KR (1) | KR101337237B1 (el) |
CN (1) | CN101277695B (el) |
AR (1) | AR054889A1 (el) |
AU (1) | AU2006274879B2 (el) |
BR (1) | BRPI0614524B8 (el) |
CA (1) | CA2615901C (el) |
CY (1) | CY1114908T1 (el) |
DK (1) | DK1912647T3 (el) |
EA (1) | EA014832B1 (el) |
ES (1) | ES2437575T3 (el) |
HK (1) | HK1124233A1 (el) |
HR (1) | HRP20131116T1 (el) |
IL (1) | IL189141A (el) |
JO (1) | JO2952B1 (el) |
MX (1) | MX2008001602A (el) |
MY (1) | MY148241A (el) |
NO (1) | NO341247B1 (el) |
NZ (1) | NZ565283A (el) |
PL (1) | PL1912647T3 (el) |
PT (1) | PT1912647E (el) |
RS (1) | RS53065B (el) |
SI (1) | SI1912647T1 (el) |
TW (1) | TWI381839B (el) |
UA (1) | UA95916C2 (el) |
WO (1) | WO2007014940A2 (el) |
ZA (1) | ZA200801108B (el) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ME01065B (me) * | 2004-01-23 | 2012-10-20 | Janssen Pharmaceutica Nv | Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora |
JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
JO3271B1 (ar) * | 2006-12-06 | 2018-09-16 | Janssen Pharmaceutica Nv | مشتقات الكوينولين المضادة للجراثيم |
JO2683B1 (en) * | 2006-12-06 | 2013-03-03 | جانسين فارماسوتيكا ان. في | Quinoline antibacterial derivatives |
US20110059948A1 (en) * | 2008-01-14 | 2011-03-10 | Jyoti Chattopadhyaya | Quinoline, naphthalene and conformationally constrained quinoline or naphthalene derivatives as anti-mycobacterial agents |
JP5246715B2 (ja) | 2009-01-27 | 2013-07-24 | 独立行政法人科学技術振興機構 | 蛋白質架橋阻害剤およびその用途 |
WO2010144102A1 (en) * | 2009-06-09 | 2010-12-16 | The United States Of America, As Represented By The Secretary Of The Army, On Behalf Of U.S. Army Medical Research And Material Command | Pentafluorosulfanyl analogs of mefloquine |
CA2869718C (en) | 2012-04-27 | 2021-05-11 | Janssen Pharmaceutica Nv | Antibacterial quinoline derivatives |
PL2841426T3 (pl) | 2012-04-27 | 2017-03-31 | Janssen Pharmaceutica N.V. | Przeciwbakteryjne pochodne chinoliny |
CN105209453B (zh) | 2012-10-16 | 2017-06-20 | 詹森药业有限公司 | ROR‑γ‑T的亚甲基连接的喹啉基调节剂 |
ES2619610T3 (es) | 2012-10-16 | 2017-06-26 | Janssen Pharmaceutica Nv | Moduladores de ROR-gamma-t de quinolinilo enlazado con heteroarilo |
CA2888485C (en) | 2012-10-16 | 2021-01-26 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of ror.gamma.t |
US9642858B2 (en) | 2012-10-30 | 2017-05-09 | University of Pittsburgh—of the Commonwealth System of Higher Education | Use of resazurin, or analogs thereof, for antibacterial therapy |
US10555941B2 (en) | 2013-10-15 | 2020-02-11 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9221804B2 (en) | 2013-10-15 | 2015-12-29 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORγt |
US9328095B2 (en) | 2013-10-15 | 2016-05-03 | Janssen Pharmaceutica Nv | Heteroaryl linked quinolinyl modulators of RORgammat |
AU2013403336A1 (en) | 2013-10-15 | 2016-04-21 | Janssen Pharmaceutica Nv | Secondary alcohol quinolinyl modulators of RORyt |
US9346782B2 (en) | 2013-10-15 | 2016-05-24 | Janssen Pharmaceutica Nv | Alkyl linked quinolinyl modulators of RORγt |
US9284308B2 (en) | 2013-10-15 | 2016-03-15 | Janssen Pharmaceutica Nv | Methylene linked quinolinyl modulators of RORγt |
US9403816B2 (en) | 2013-10-15 | 2016-08-02 | Janssen Pharmaceutica Nv | Phenyl linked quinolinyl modulators of RORγt |
US9624225B2 (en) | 2013-10-15 | 2017-04-18 | Janssen Pharmaceutica Nv | Quinolinyl modulators of RORγt |
GB201904796D0 (en) * | 2019-04-04 | 2019-05-22 | Univ Sheffield | Antimicrobial agent |
AR121683A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-heteroarilalquil-2-(heterociclil y heterociclilmetil)acetamida como agonistas de sstr4 |
AR121682A1 (es) * | 2020-03-31 | 2022-06-29 | Takeda Pharmaceuticals Co | Derivados de n-(heterociclil y heterociclilalquil)-3-bencilpiridin-2-amina como agonistas de sstr4 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9317491D0 (en) | 1993-08-23 | 1993-10-06 | Fujisawa Pharmaceutical Co | New compound and a process for preparation thereof |
US6376670B1 (en) * | 1997-06-19 | 2002-04-23 | Sepracor Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
US6103905A (en) * | 1997-06-19 | 2000-08-15 | Sepracor, Inc. | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
GB9914486D0 (en) * | 1999-06-21 | 1999-08-18 | Smithkline Beecham Plc | Medicaments |
GB9917408D0 (en) * | 1999-07-23 | 1999-09-22 | Smithkline Beecham Plc | Compounds |
GB0101577D0 (en) * | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
TW200409637A (en) * | 2002-06-26 | 2004-06-16 | Glaxo Group Ltd | Compounds |
ES2395237T3 (es) | 2002-07-25 | 2013-02-11 | Janssen Pharmaceutica N.V. | Derivados de quinolina como compuestos intermedios para inhibidores micobacterianos |
CN101817815A (zh) * | 2002-10-10 | 2010-09-01 | 莫弗凯姆联合化学股份公司 | 具有杀菌活性的化合物 |
DE10316081A1 (de) * | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
MXPA06005686A (es) * | 2003-11-20 | 2006-08-17 | Janssen Pharmaceutica Nv | 2-quinolinonas y 2-quinoxalinonas 7-fenilaquilo sustituidas como inhibidores de la poli(adp-ribosa)polimerasa. |
SG151249A1 (en) * | 2003-12-05 | 2009-04-30 | Janssen Pharmaceutica Nv | 6-substituted 2-quinolinones and 2-quinoxalinones as poly(adp-ribose) polymerase inhibitors |
ME01065B (me) * | 2004-01-23 | 2012-10-20 | Janssen Pharmaceutica Nv | Derivati kvinolina i njihova upotreba kao mikobakterijskih inhibitora |
JO2952B1 (en) | 2005-08-03 | 2016-03-15 | جانسين فارماسوتيكا ان. في | Quinoline derivatives acting as antibacterial agents |
-
2006
- 2006-07-18 JO JO2006233A patent/JO2952B1/en active
- 2006-07-31 EP EP06778081.7A patent/EP1912647B1/en active Active
- 2006-07-31 SI SI200631705T patent/SI1912647T1/sl unknown
- 2006-07-31 PL PL06778081T patent/PL1912647T3/pl unknown
- 2006-07-31 AU AU2006274879A patent/AU2006274879B2/en not_active Ceased
- 2006-07-31 RS RS20130539A patent/RS53065B/en unknown
- 2006-07-31 ES ES06778081.7T patent/ES2437575T3/es active Active
- 2006-07-31 BR BRPI0614524A patent/BRPI0614524B8/pt not_active IP Right Cessation
- 2006-07-31 WO PCT/EP2006/064856 patent/WO2007014940A2/en active Application Filing
- 2006-07-31 DK DK06778081.7T patent/DK1912647T3/da active
- 2006-07-31 PT PT67780817T patent/PT1912647E/pt unknown
- 2006-07-31 NZ NZ565283A patent/NZ565283A/en not_active IP Right Cessation
- 2006-07-31 EA EA200800501A patent/EA014832B1/ru unknown
- 2006-07-31 US US11/997,182 patent/US8017606B2/en active Active
- 2006-07-31 MX MX2008001602A patent/MX2008001602A/es active IP Right Grant
- 2006-07-31 KR KR1020087005066A patent/KR101337237B1/ko active IP Right Grant
- 2006-07-31 UA UAA200801433A patent/UA95916C2/ru unknown
- 2006-07-31 JP JP2008524508A patent/JP5410753B2/ja not_active Expired - Fee Related
- 2006-07-31 CN CN200680036637XA patent/CN101277695B/zh not_active Expired - Fee Related
- 2006-07-31 CA CA2615901A patent/CA2615901C/en active Active
- 2006-08-01 MY MYPI20063726A patent/MY148241A/en unknown
- 2006-08-02 AR ARP060103371A patent/AR054889A1/es not_active Application Discontinuation
- 2006-08-02 TW TW095128223A patent/TWI381839B/zh active
-
2008
- 2008-01-31 IL IL189141A patent/IL189141A/en active IP Right Grant
- 2008-02-01 ZA ZA200801108A patent/ZA200801108B/xx unknown
- 2008-02-25 NO NO20080955A patent/NO341247B1/no not_active IP Right Cessation
-
2009
- 2009-02-05 HK HK09101044.5A patent/HK1124233A1/xx not_active IP Right Cessation
-
2013
- 2013-11-22 HR HRP20131116TT patent/HRP20131116T1/hr unknown
- 2013-12-11 CY CY20131101116T patent/CY1114908T1/el unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1114908T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
CY1114318T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
CY1112247T1 (el) | Παραγωγα κινολινης για τη θεραπευτικη αντιμετωπιση της λανθανουσας φυματιωσης | |
ECSP055611A (es) | Compuestos miméticos de glucocorticoides, métodos de prepararlos, composiciones farmacéuticas | |
CY1113535T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
GEP20084439B (en) | Nitrogen-containing heterocyclic derivatives and pharmaceutical use thereof | |
AR051989A1 (es) | Derivados de quinolina como agentes antibacterianos | |
CY1113579T1 (el) | Παραγωγα κινολινης ως αντιβακτηριακοι παραγοντες | |
CY1113733T1 (el) | Παραγωγα κινολινονης και οι φαρμακευτικες συνθεσεις αυτων | |
NO20080499L (no) | Kinolinderivater som antibakterielle midler | |
CY1112230T1 (el) | Αντιβακτηριακα παραγωγα κινολινης | |
NO20080481L (no) | Kinolinderivater som antibakterielle midler | |
BRPI0414778A (pt) | 6-aril-7-halo-imidazo[1,2-a]pirimidinas como agentes anticáncer |